Astellas remains in the industry doghouse in the U.K. for bad behavior

first_img By Ed Silverman June 23, 2017 Reprints Astellas remains in the industry doghouse in the U.K. for bad behavior What’s included? Kristoffer Tripplaar/Sipa USA/AP GET STARTED Log In | Learn More Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. What is it? Ed Silverman STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.center_img @Pharmalot Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. About the Author Reprints In a highly unusual move, the pharmaceutical industry trade group in the United Kingdom has extended a suspension given Astellas last year for another 12-month period, after finding the drug maker engaged in yet another round of egregious behavior.The latest infractions demonstrated “wholly inadequate oversight and control” at its U.K. and European operations and a “lamentable lack of concern for patient safety,” according a stern statement issued by the Association of the British Pharmaceutical Industry. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED [email protected] Pharmalot Tags pharmaceuticalsSTAT+last_img read more